

## PAN MERSEY AREA PRESCRIBING COMMITTEE MEETING

**Minutes of the Meeting held on Wednesday 12 March 2014 in The Gallery,  
Huyton Civic Suite, Civic Way off Poplar Bank, Huyton. L36 9GD**

**Present:**

Peter Johnstone (CHAIR)	Prescribing Commissioner – Liverpool CCG
Catrin Barker	Chief Pharmacist – Alder Hey Children’s NHS Foundation Trust
Nicola Baxter	Head of Medicines Optimisation – West Lancs CCG
Dr. Catherine Doyle	Clinical Lead Medicines Management – Warrington CCG
Dr. Michael Ejuoneatse	Clinical Lead for Medicines – St Helens CCG
Dr. Janice Eldridge	GP Medicines Management Lead – Southport & Formby CCG
Dr. Claire Forde	CCG Governing Body Member-Prescribing Lead – Halton CCG
Simon Gelder	Chief Pharmacist – St Helens & Knowsley Teaching Hospitals NHS Trust
Margaret Geoghegan	Head of Medicines Management – St Helens CCG
Gillian Gow	Chief Pharmacist – Liverpool Heart and Chest FT
Dr. Aftab Hossain	Clinical Lead, Prescribing – Knowsley CCG
Isam Badhawi	Senior Pharmacist, Liverpool Women’s NHS Foundation Trust
Jenny Jones	Principal Pharmacist Medicines Management – Warrington & Halton Hospitals NHS Foundation Trust
Jennifer Lunn	Pharmaceutical Adviser & Team Lead, Medicines Management – Warrington CCG
Dr. Sid McNulty	Consultant Endocrinologist – St Helens & Knowsley Teaching Hospitals NHS Trust
Dr. Neil Mercer	Consultant Anaesthetist/Chair Drug & Therapeutics – Aintree University Hospitals NHS Trust
Paul Mooney (representing Alison Ewing)	Senior Pharmacist – The Royal Liverpool & Broadgreen University Hospitals NHS Trust
Graham Pimblett	Medicines Management Team Leader – Knowsley CCG
Brendan Prescott	CCG Lead Medicines management – South Sefton CCG and Southport & Formby CCG (NHS Sefton)
Lucy Reid	Lead Pharmacist - Halton Locality Medicines Management Team
Dr. Shamim Rose	GP Prescribing Lead & Board Sponsor – Liverpool CCG
Steven Simpson	Southport and Ormskirk NHS Trust
Dave Thornton	Principal Pharmacist, Clinical Services University Hospital Aintree – Representing Mags Norval
Sarah McParland (representing Lorraine Prescott)	Senior Pharmacist – 5-Boroughs Partnership NHS Foundation Trust
Dr. Anna Ferguson	GP Clinical Lead – South Sefton CCG

**In Attendance:**

Donna Gillespie-Greene	Joint Deputy Head of Medicines Management Cheshire and Merseyside Commissioning Support Unit
Maureen Hendry	Practice pharmacist – Matchworks Interface support pharmacist, Liverpool Community Health

Anne Henshaw	Senior Pharmacist Cheshire & Merseyside Commissioning Support Unit
Clare Moss	Senior Pharmacist Cheshire & Merseyside Commissioning Support Unit
Graham Reader	Senior Pharmacist Cheshire & Merseyside Commissioning Support Unit
Helen Stubbs	Senior Pharmacist Cheshire & Merseyside Commissioning Support Unit

1	<p><b>APC/14/19 – Welcome and Apologies for Absence</b> The Chair welcomed the Committee members to the meeting.</p> <p>Apologies were received from the following members: Alison Ewing (RLBUHT), Paul Skipper (RLBUHT), Cassandra Edgar (St Helens &amp; Knowsley NHS Trust), Calum Semple (Alder Hey), Alison Butt (LCH), Cecilia Jukka (Southport &amp; Ormskirk), Heather Tomlinson (Bridgewater), Tom Kennedy (RLBUHT), Erika Baker (CMCSU).</p>	
2	<p><b>APC/14/20 – Declarations of Interest and Quoracy check</b> A quoracy check informed that there were 7 Primary Care clinicians and 2 Secondary Care Consultants present at this meeting. This meeting was quorate.</p> <p>There were no declarations of interest at this meeting.</p>	
3	<p><b>APC/14/21 – Minutes of the previous meeting and matters arising.</b></p> <p><b>14/21/01 – Minutes from the previous meeting</b> The Chair asked the members for any inaccuracies in the draft minutes.</p> <p><b>Page 3 - Ferrous Fumarate:</b> The following addition to the Minutes was agreed - clarification to be given that ferrous sulphate was also still a first choice oral iron preparation alongside ferrous fumarate</p> <p><b>Matters Arising:</b></p> <p><b>14/21/02 – Prescribing overseas advice</b> Action completed.</p> <p><b>14/21/03 – Magnesium Glycerophosphate</b> All action has been completed.</p> <p><b>14/21/04 – Rifaximin</b> Costing and usage information to be brought to April APC meeting.</p> <p><b>14/21/05 – Doxazosin m/r statement</b> Action completed.</p> <p><b>14/21/06 – Diabetes Guidelines update</b> Agreed for Chair action to sign off, which was confirmed by Chair.</p> <p><b>14/21/07 – Dexamethasone intravitreal implant for non-infectious uveitis</b> It was suggested that it was the APC role to raise the question for CCG Boards that, as the duration and frequency of administration of Dexamethasone intravitreal implant was uncertain, they may wish to consider asking provider Trusts to provide data on this over a fixed period and for these data to be reviewed by the Committee prior to any extending of approval for this treatment into the future. It was proposed that Trusts must collect 12 months' of data to April 2015 regarding number of patients treated in each hospital, number of doses each patient has received and the</p>	<p><b>Action: DGG</b></p> <p><b>Action: EB / CCG Meds Man Leads</b></p>

	<p>anticipated or actual duration of treatment for each patient. Results to be reported back to this Committee by Trusts after a further 3 months from April 2015 for further review of ongoing use into the future. This was agreed by the Committee. CCG representatives to suggest this to their Boards when they consider approval of the recommendation to commission Dexamethasone intravitreal implant for non-infectious uveitis.</p> <p><b>14/21/08 – Safety update</b> CM confirmed that follow up action is being progressed.</p> <p><b>14/21/09 – Shared Care</b> Action completed. Gone to consultation.</p> <p><b>14/21/10 – Patient and Public Representation</b> Patient representatives were invited but none are in attendance today. This is something which requires more work, to encourage attendance. Deferred until April's APC meeting.</p>	
4	<p><b>APC/14/22 – New Medicines</b></p> <p><b>14/22 – Aflibercept in CRVO</b> NICE TA published earlier than originally anticipated. Aflibercept is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only by ophthalmologists and in accordance with NICE TA305. The costing information has been produced and will be circulated to CCG Medicines Management Leads with the APC report. The PAS discount has to be signed up to by each individual provider. The Chair asked if we can assume that hospitals have signed up to PAS. The members felt that that the CSU should obtain assurances to that effect. This will be discussed at the Heads and Chiefs' Meeting on 14 March 2014. The Committee approved the use of Aflibercept.</p>	
5	<p><b>APC/14/23 – Formulary and Guidelines</b></p> <p><b>14/23/01 – Primary Care Antimicrobial Guidelines – UTI section</b> These guidelines have been re-drafted. Three minor amendments/corrections were raised and approved. During this year's consultation, comments were received around the formatting of the current document, and it was proposed that a reformatted document would be available for September 2014. The HPA guidelines are due out approximately Nov 2014, so it is planned to have guidelines ready for consultation by early Spring 2015. If there are no significant changes then it was agreed that simply those changes should be made rather than rewrite all. A quotation for printing has been obtained and HS asked if someone would co-ordinate orders for printed copies – To be discussed at Heads and Chiefs' Meeting on 14 March 2014.</p> <p><b>14/23/02 – Ibuprofen &amp; Naproxen statement</b> The FGSG recommended having the previous statement updated and this was presented. A deletion of reference to COX2 inhibition and GI side effects was agreed and correction of % for each NSAID prescribed in ePACT was agreed. This was approved (subject to the minor amendments above).</p> <p><b>14/23/03 – Triptorelin statement</b> Recommended triptorelin to be used as first-line gonadorelin analogue. Statement already exists in Mid-Mersey and FGSG recommended that a Pan Mersey version was required. This document is not advocating switching existing patients on other analogues to triptorelin. It was agreed that Bicalutamide should be removed as a specific anti-androgen example and a statement that sub-cutaneous alternatives may be</p>	<b>Action: HS</b>

	<p>preferable in anticoagulated patients was agreed. This was approved subject to the above minor amendments.</p> <p><b>14/23/04 – N-acetylcysteine - Amber RAG rating</b> Although this drug is Amber status in mid-Mersey, it has previously been regarded as Red in North Mersey. FGSG recommended that it is classified as Amber across Pan Mersey. This drug is a licensed product in Germany but unlicensed in UK and is used to treat interstitial pulmonary fibrosis. It was roughly estimated that about 60 patients are prescribed it in Liverpool Heart and Chest Hospital therefore possibly £55,000 cost implication to CCGs of transfer of prescribing to primary care. It was agreed however that before any change to RAG status could be agreed that the FGSG should examine the evidence of benefit in this condition and that a statement should be produced and brought to APC for consideration following the normal process.</p> <p><b>14/23/05 – Formulary amendments</b> Minor changes were agreed as follows: Addition Diltiazam 2% cream section 1.7.4 – Green 2<sup>nd</sup> line GTN 0.4% cream section 1.7.4 – change from Amber to Green 2nd line Lansoprazole FasTabs section 1.3.5 - change from Amber to Green (2nd line) Macrogol oral powder + Mag citrate/ sod picosulphate section 1.6.5 – change from Amber to Green (Red in some areas depending on service delivery) for bowel cleansing Omeprazole MUPs section 1.3.5 - change from Amber to Green (2nd line) Oily phenol injection section 1.7.3 – addition to formulary as Red Pancreatin capsules section 1.9.4 - change from Red to Amber Sucralfate section 1.3.3 – change from Amber to Green.</p>	<b>Action: GR</b>
6	<p><b>APC/14/24 – Safety</b></p> <p><b>14/24/01 – Safety update</b> The three month trial of the Interface forms has been completed. Forms will be collated and will be presented to the Safety Group next week. Feedback from completed forms was requested, in the future. Safety group to review and amend form as required and review process. It was requested that the report is brought to APC in April. CM reported that a drug alert audit is also on-going. It was requested that the audit be amended to include recalls of each class. CM to amend. CM was asked if the CSU contacted Pharmacy QC Unit as they have always audited drug recalls – CM confirmed that this will be done.</p>	<b>Action: CM</b>
7	<p><b>APC/14/25 – Shared Care</b></p> <p><b>14/25/01 – Shared Care update</b> The Shared Care task and finish group will meet on 27<sup>th</sup> March.</p>	
8	<p><b>APC/14/26 – Any Other Business</b></p> <p><b>14/26/01 – CCG Approval and Notification of NICE TA Related Statements</b> Providers are requesting feedback of the matters agreed at the APC meeting. The APC members need assurance from the providers that they take recommendations back and something is being done with them. Assurance is required that what is on the statements is being communicated/disseminated to clinicians. This information should be sent to the following CMCSU email address: <a href="mailto:medsmanagementbevan@cmcsu.nhs.uk">medsmanagementbevan@cmcsu.nhs.uk</a></p>	<b>Action: DGG</b>

	<p><b>14/26/02 – Minutes - Changes</b>  DGG reported that the governance with regard to Minutes has been checked and that it is not a legal requirement to have them signed off by the Chair. Therefore it was proposed that the Minutes should no longer be signed off by the Chairperson which will save time as the whole process takes up to 2 months.  There was unanimous agreement.  The Chair proposed that there should be a deadline of 10 working days for comments/corrections/amendments of the Minutes so that these changes are made prior to the meeting thus negating the need to spend time during the meeting going through these details.  All were in agreement.</p>	<p><b>Action: ALL</b></p>
9	<p><b>APC/14/27 – Date, Time and Venue of the next meeting</b></p> <p>The next meeting will be held on Wednesday 30 April 2014 at 1:30 – 3:30pm in The Gallery, Huyton Civic Suite, Civic Way off Poplar Bank, Huyton. L36 9GD  The Chair will be Dr M G Semple.</p>	

***The agenda and minutes of this meeting may be made available to public and persons outside of The Pan Mersey Area Prescribing Committee Health Community in order to comply with requests made under the Freedom of Information Act 2000.***